SCI Impact Surveys (2018)
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKALAMANAOAPAQARASATAUAVAWAXAYAZBABBBCBDBEBFBGBHBIBJBKBLBMBNBOBPBQ
1
For sources, see "Methods" sheet
2
Statistical significance of changes as reported by SCI is indicated by *s, where: ** = p < 0.01, * = p < 0.05. We have not verified these statistical tests.
3
Schistosoma haematobium
Schistosoma mansoni
HookwormAscarisTrichuris
4
Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)Prevalence (%)Heavy Prevalence (%)Mean Intensity (epg)
5
CountryYearWhich follow-up?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Baseline PrevalencePrevalence at Follow-UpChange in PrevalenceSignificant?Baseline Heavy PrevalenceHeavy Prevalence at Follow-UpChange in Heavy PrevalenceSignificant?Baseline IntensityIntensity at Follow-UpChange in IntensitySignificant?Notes
6
Niger1st Follow-up75.4%38.0%-37.4%21.8%4.6%-17.2%
Very low prevalence
N/AN/AN/AN/AN/AN/AN/ALow prevalenceN/AN/AN/AN/AN/AN/AN/A
Very low prevalence
N/AN/AN/AN/AN/AN/AN/AFigures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
7
Burundi (pilot)
1st/3rd/4th Follow-up (see cell notes)
Very low prevalence
N/AN/AN/AN/AN/AN/AN/A12.7%1.7%-11.0%201-1917.8%2.7%-15.1%1624814.9%10.1%-4.8%3.2%2.4%-0.8%Figures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
8
Burundi (other schools)
1st/3rd/4th Follow-up (see cell notes)
Very low prevalence
N/AN/AN/AN/AN/AN/AN/A6.2%0.7%-5.5%83-515.1%5.4%-9.7%158-721.6%9.1%-12.5%10.4%4.3%-6.1%Figures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
9
Liberia20131st Follow-up20.2%9.0%-11.2%**9.0%2.5%-6.5%*26.2%15.0%-11.2%**0.2%1.0%0.8%*15.2%9.5%-5.7%Not reported
No participants heavily infected at baseline
N/AN/AN/A12.8%1.3%-11.5%Figures taken from the 'Changes in worm prevalence and intensity' table in an earlier page on SCI: https://www.givewell.org/charities/schistosomiasis-control-initiative/january-2017-version#Prevalence_and_intensity_studies
10
Cote d'Ivoire (Phase 1 schools)
20161st Follow-up7.5%9.2%1.7%No1.9%2.1%0.2%No5.984.66-1.32Not reported18.3%20.6%2.3%No2.9%1.9%-1.0%
Significant at 10% level
46.0127.86-18.15Not reported16.7%4.4%-12.3%**0.3%0.0%-0.3%N/A57.227.88-49.34Not reported3.2%1.2%-2.0%**0%0%0%N/A146.6726.06-120.61Not reported1.1%1.0%-0.1%No0%0%0%N/A21.416.69-14.72Not reported
11
Tanzania20171st Follow-up5.3%1.3%-4.0%**1.4%0.2%-1.2%**2.330.01-2.32**7.4%7.6%0.2%No1.1%1.0%-0.1%No2.3012.8910.59Not reported11.9%5.4%-6.5%Not reported0.0%0.0%0.0%N/A66.6714.97-51.70Not reported4.9%5.6%0.7%Not reported0%0%0%N/A141.5992.39-49.2Not reported1.7%4.1%2.4%Not reported0%0%0%N/A4.2110.506.29Not reportedSignificance tests taken from comments in commentary of dashboard, rather than results tables
12
Burundi20173rd Follow-up
Very low prevalence
N/AN/AN/AN/AN/AN/AN/A17.5%4.5%-13.0%**1.8%0.4%-1.4%**28.305.40-22.90**19.0%1.4%-17.6%**0%0%0.0%N/A19.601.80-17.80**8.2%3.0%-5.2%**0%0%0%N/A155.553.8-101.7**2.8%1.3%-1.5%**0%0%0%N/A1.70.8-0.9**
13
Madagascar20171st Follow-up30.8%25.2%-5.6%**15.3%8.0%-7.3%**62.3322.24-40.09**5.1%3.7%-1.4%*0.9%0.5%-0.4%*14.318.05-6.26N/A0.9%0.6%-0.3%No0%0%0.0%N/A2.293.701.41N/A3.0%7.2%4.2%**0%0%0%N/A116.42220.68104.26Not reported0.9%1.2%0.3%No0%0%0%N/A0.964.233.27Not reported
14
Ethiopia2016/171st Follow-up3.4%0.1%-3.3%Not reported0.2%0.0%-0.2%Not reported0.540.01-0.53Not reported5.6%5.5%-0.2%Not reported0.6%0.2%-0.4%Not reported10.405.54-4.86Not reported6.0%5.7%-0.3%Not reported0.01%0.01%0.0%Not reported11.1621.2810.12Not reported10.9%10.0%-0.9%Not reported0%0%0%N/A188.1205.417.3Not reported4.2%5.4%1.2%Not reported0%0%0%N/A8.2920.5712.28Not reported
15
Malawi20174th Follow-up9.2%2.4%-6.9%**1.6%0.5%-1.1%**3.590.57-3.02Not reported2.2%0.4%-1.8%*0.2%0.1%-0.1%No2.091.05-1.04Not reported0.0%0.1%0.1%N/A0%0%0.0%N/A00.020.02N/A0.0%0.0%0.0%N/A0%0%0%N/A000N/A0%0%0%N/A0%0%0%N/A000N/A
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...
Main menu